Home Today’s Briefing Deep Dives In Play Trending For You Discover My Stack Saved Off Radar Search

Loading today’s stories

Today

AI-assisted reporting, grounded in a per-article claim ledger. Perspective Coverage and Reality Strip separate source viewpoints from evidence, adoption, hype, incentives, and confidence.

Today

Front Page
Today’s Briefing
Newsletters
Trending
For You
Discover
My Stack
Saved
Off Radar
Search

Sections

Security
Build
Invest
Product
Leadership
Science

Company

About
Mission
How this is made
Evidence Index
The desks
The sources we read
Corrections
Press and brand
The daily edition

Trending now

Consumer AI Agents
Endpoint defense evasion
Adware as a delivery channel
ValleyRAT / Winos 4.0
China-Nexus Threat Activity
US AI Legislation
Critical infrastructure resilience
Indirect prompt injection
Medical Device Regulation
Inference cost economics

How this is made

Today For You My Stack Off Radar Search

Commissioner's National Priority Voucher pilot — standard — Clarity Today

standard

Commissioner's National Priority Voucher pilot

FDA pilot whose vouchers target review of final applications in one to two months instead of the standard ten to twelve.

Known aliases

CNPV

Relationships

No evidence-backed relationships are recorded.

Current clusters

science1 distinct publisher

A RAS inhibitor wins FDA approval in metastatic pancreatic cancer at $39,800 a month

Revolution Medicines' daraxonrasib nearly doubled median overall survival in previously treated patients. Investors sat still anyway, because the unresolved variable is now what payers will absorb.

Publishers:genengnews.com

Reality

Evidence70
Adoption34
Hype gap+16
Incentives72

Confidence61